Related Experiment Videos
Sildenafil for pulmonary hypertension.
P Kanthapillai1, Tj Lasserson, Eh Walters
1Luton and Dunstable NHS Trust, Lewsey Road,, Luton, Hertfordshire, UK, LU4 0DZ. Parthipan.Pillai@ldh-tr.anglox.nhs.uk
The Cochrane Database of Systematic Reviews
|October 21, 2004
Summary
Sildenafil effectively dilates pulmonary arteries in pulmonary hypertension (PH). While showing short-term benefits and good tolerance, larger studies are needed to confirm long-term efficacy for PH patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Pulmonary Hypertension (PH) is characterized by pulmonary arteriolar vasoconstriction.
- PH can be primary (unknown cause) or secondary (known cause).
- Vasodilator therapies are a key treatment for PH.
Purpose of the Study:
- To evaluate the clinical efficacy of sildenafil in treating primary and secondary pulmonary hypertension.
- Sildenafil's mechanism involves phosphodiesterase type V (PDE5) inhibition.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) up to November 2003.
- Included studies assessed sildenafil in participants with primary pulmonary hypertension (PPH) and secondary pulmonary hypertension (SPH).
- Data extraction and analysis by two independent reviewers; continuous and dichotomous data were pooled.
Main Results:
- Four studies with 77 participants met inclusion criteria.
- Acute administration demonstrated pulmonary vasodilatory effects.
- Long-term studies showed symptom improvement and good tolerability, with one study noting improved fatigue domains.
Conclusions:
- Small participant numbers limit the validity of observed effects.
- Further validation is required for long-term outcomes like functional class, mortality, and exercise capacity.
- Larger studies are necessary to establish long-term clinical benefits of sildenafil in PH.